Mirum Pharmaceuticals Stock Gains as Hepatitis Drug Meets Late-Stage Trial Goals

Key Facts

1Mirum Pharmaceuticals announced its experimental hepatitis drug reduced virus levels in patients.

2The late-stage study successfully met its primary goal.

Mirum Pharmaceuticals announced its experimental hepatitis drug reduced virus levels in patients during a clinical study. Reuters reported that the late-stage study successfully met its primary goal, marking a significant milestone for the company's clinical pipeline.

MIRM closed at $89.7 on September 25, 2026, prior to the announcement of these clinical results. The stock reached a high of $90.81 and a low of $88.28 during that session, as the company moved toward meeting the primary endpoints of its experimental treatment program.